Bevacizumab in combination with octreotide rescues a patient with liver cirrhosis, GAVE syndrome and refractory hemorrhage – a case report
Zeitschrift für Gastroenterologie · 01.03.2023 · 61 (03) · 275-279
DOI: 10.1055/a-1959-2660 ↗Kurz gefasst
Fallbericht in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.03.2023. Verfasst von Simon Johannes Gairing und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany. Hauptthemen laut MEDLINE: Gastric Antral Vascular Ectasia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Gastric antral vascular ectasia (GAVE) syndrome is a rare but often challenging etiology of upper gastrointestinal bleeding (UGIB). We report on a 60-year-old patient with liver cirrhosis, GAVE syndrome and recurrent and refractory GAVE-related UGIB. During a 5-month hospital stay, the patient required a total of 82 packed red blood cells (pRBCs) and 23 gastroscopies. All endoscopic approaches, including multiple argon plasma coagulation and band ligation sessions, remained unsuccessful. Antrectomy was waived because of the high perioperative mortality risk in Child-Pugh B liver cirrhosis. TIPS insertion also failed to control the bleeding. Only continuous intravenous octreotide infusion slowed the bleeding, but this forced the patient to be hospitalized. After 144 inpatient days, administration of subcutaneous octreotide allowed the patient to be discharged. However, the patient continued to require two pRBCs every 2–3 weeks. Based on recently published data, we treated the patient with bevacizumab (anti-VEGF antibody) off-label at a dose of 7.5 mg/kg body weight every three weeks in nine single doses over six months. Since the first administration, the patient has remained transfusion-free, has not required hospitalization, and leads an active life, working full-time. He remains on octreotide, which has been reduced but not yet discontinued. Additionally, no adverse events were observed. Thus, in patients with liver cirrhosis and refractory GAVE-related hemorrhage, bevacizumab combined with subcutaneous octreotide should be considered as an effective and durable pharmacological treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany.
- Department of Diagnostic and Interventional Radiology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany.
- Department of Gastroenterology, Hematology, Oncology and Endocrinology, Hospital Dortmund, Dortmund, Germany.
ORCID-Profile: Simon Johannes Gairing, Christian Labenz, Jörn M Schattenberg, Friedrich Foerster
Zitieren
APA
Gairing, S. J., Schleicher, E. M., Müller, L., Labenz, C., Darstein, F., Grimm, D., Sivanathan, V., Weinmann, A., Wörns, M. A., Kloeckner, R., Pitton, M. B., Thieringer, F., Rahman, K. F., Galle, P. R., Schattenberg, J. M., & Foerster, F. (2023). Bevacizumab in combination with octreotide rescues a patient with liver cirrhosis, GAVE syndrome and refractory hemorrhage – a case report. Zeitschrift für Gastroenterologie, 61(03), 275-279. https://doi.org/10.1055/a-1959-2660
Vancouver
Gairing SJ, Schleicher EM, Müller L, Labenz C, Darstein F, Grimm D, et al. Bevacizumab in combination with octreotide rescues a patient with liver cirrhosis, GAVE syndrome and refractory hemorrhage – a case report. Zeitschrift für Gastroenterologie. 2023;61(03):275-279. doi:10.1055/a-1959-2660
BibTeX
@article{Gairing2023,
author = {Gairing, Simon Johannes and Schleicher, Eva Maria and Müller, Lukas and Labenz, Christian and Darstein, Felix and Grimm, Daniel and Sivanathan, Visvakanth and Weinmann, Arndt and Wörns, Marcus-Alexander and Kloeckner, Roman and Pitton, Michael B and Thieringer, Florian and Rahman, Khan Fareed and Galle, Peter Robert and Schattenberg, Jörn M and Foerster, Friedrich},
title = {Bevacizumab in combination with octreotide rescues a patient with liver cirrhosis, GAVE syndrome and refractory hemorrhage – a case report},
journal = {Zeitschrift für Gastroenterologie},
year = {2023},
volume = {61},
number = {03},
pages = {275--279},
doi = {10.1055/a-1959-2660}
}
EUVIMED